Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer

Key Takeaway: The article discusses advancements in targeting the CD40L pathway to enhance immunosuppression therapy, which could lead to longer-lasting organ transplants. This innovative approach aims to improve patient outcomes and transform lives through better organ transplant management. The focus on this pathway highlights the potential for significant advancements in transplant medicine.
Price reaction · baseline $4.645 (2024-12-11T18:38:00.000Z) · hit during market hours · clean, no other ELDN news in the window
day 0 close · peak
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Focus on improving immunosuppression therapy.
  • Aims to enhance organ transplant longevity.
  • Potential for significant patient impact.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the focus of the article?

The article focuses on targeting the CD40L pathway to improve immunosuppression therapy.

How could this research impact organ transplants?

It aims to enhance the longevity of organ transplants and improve patient outcomes.

What is the significance of the CD40L pathway?

The CD40L pathway is crucial for advancing immunosuppression therapies in transplant medicine.

Last updated: Dec 11, 2024